Full-Time

Global Clinical Lead

Renal Cancer Imaging

Posted on 7/29/2024

Telix Pharmaceuticals

Telix Pharmaceuticals

201-500 employees

Develops targeted radiation therapies for cancer

Biotechnology
Healthcare

Senior, Expert

Remote in USA

Category
Diagnostics & Laboratory Professionals
Physicians & Surgeons
Medical, Clinical & Veterinary
Required Skills
Data Analysis
Requirements
  • Bachelor’s degree in biomedical science or imaging-related field is required, Master’s preferred.
  • 10+ years of experience in clinical imaging using CT and PET
  • 5+ years of experience in clinical development within the pharmaceutical or biotechnology industry
  • Strong knowledge of clinical trial design, methodology, and regulatory requirements
  • Track record of working effectively with imaging CROs and vendor management
  • Experience in authoring clinical study and regulatory documents
  • Experience in oncology
Responsibilities
  • Develop and execute on imaging studies to enable the advancement of diagnostic and therapeutic radiopharmaceuticals
  • Lead development of imaging sections of clinical study documentation and regulatory documents
  • Lead the design, analysis, review, and quality control of imaging data to ensure accuracy and quality
  • Oversight of third-party vendors, such as imaging CROs
  • Collaborate with Global Clinical Leads, Global Program Leads, Biostatistics, Clinical Operations, and other cross-functional colleagues to ensure strategic and effective implementation of novel imaging approaches in clinical studies
  • Prepare and deliver presentations, proposals, and reports for senior management, partners, and other stakeholders
Telix Pharmaceuticals

Telix Pharmaceuticals

View

Telix Pharmaceuticals develops and sells products aimed at improving the diagnosis and treatment of cancer and rare diseases. The company focuses on creating therapeutic and diagnostic solutions that use targeted radiation, which helps healthcare providers make better treatment decisions and offers personalized therapy for patients with significant medical needs. Their product pipeline includes treatments for prostate and kidney cancers, glioma, sarcoma, and bone marrow conditioning. Telix operates a global supply chain to manufacture and distribute its products, generating revenue through sales to healthcare institutions. The company emphasizes sustainability, patient care, and ethical practices, aiming to create value for patients, shareholders, and employees.

Company Stage

IPO

Total Funding

$14.8M

Headquarters

Melbourne, Australia

Founded

2015

Growth & Insights
Headcount

6 month growth

0%

1 year growth

0%

2 year growth

2%
Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of ImaginAb's assets accelerates development of next-generation cancer therapies.
  • New cyclotrons in Brussels enhance production capabilities for radiopharmaceuticals.
  • Expansion of North American network strengthens distribution capabilities in a key market.

What critics are saying

  • Integration challenges with ImaginAb's technology could delay new therapy development.
  • Retirement of co-founder Andreas Kluge may disrupt leadership continuity.
  • Rapid expansion into North America could strain operational resources and pose integration risks.

What makes Telix Pharmaceuticals unique

  • Telix focuses on molecularly-targeted radiation therapy for prostate, renal, and glioblastoma cancers.
  • The company integrates diagnostics and therapy, offering personalized treatment for complex diseases.
  • Telix's global supply chain ensures availability and delivery of specialized products worldwide.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Annual Performance Bonus

Equity-Based Incentive Program

Paid Vacation

Paid Wellness Days

Hybrid Work Options

Remote Work Options

INACTIVE